NVCR - Why Novocure Stock Skyrocketed Today
Shares of Novocure (NASDAQ: NVCR) soared nearly 50% on Tuesday after the oncology company provided an update on a phase 3 trial of its experimental lung cancer treatment.
An independent data monitoring committee (DMC) informed Novocure that an interim analysis for the study would be accelerated after data from 210 patients showed no evidence of increased systemic toxicity.
Moreover, the DMC said it was likely "unnecessary and possibly unethical" to enroll the prior target number of patients into the control group and recommended a reduced timeline for the clinical trial.
For further details see:
Why Novocure Stock Skyrocketed Today